NervGen Pharma Completes $9.2 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 12, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public […]
NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 5, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that, due to strong demand, the Company […]
NervGen Pharma Announces $5,000,000 Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that it has entered into an agreement […]
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 / Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial
Vancouver, Canada. November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience 2021 conference. NervGen’s Chief Medical Officer, Dr. Daniel […]
The Cost of Disability
By Codi Darnell November 2, 2021 The monthly budget – while I love a good spreadsheet (seriously, I’m a bit of a nerd), this one is not it. If my computer was an attic, my Monthly Budget spreadsheet would be loose in the back of a binder, the three holes ripped open long ago, and […]
NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board
Vancouver, Canada. October 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field […]
Expanding the Status Quo – Diversifying Mainstream Media
By Codi Darnell October 19, 2021 It’s October – the month of pumpkin spice, Canadian Thanksgiving and Halloween. While pumpkin spice is the highlight for me, for the three kids in our house, it’s Halloween. And the search for the perfect costume started early. It was possibly still September when I ventured onto Party City’s […]
NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile
Vancouver, Canada. October 18, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a positive update on its Phase 1 program with NVG-291 in healthy volunteers at the 146th Annual Meeting of the American Neurological Association. […]
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
Cincinnati, Ohio. October 4, 2021 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its release of the Fiscal Year 2022 National Defense […]
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
Vancouver, Canada. September 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. (“Imeka”), currently the only neuroimaging company that combines artificial intelligence and diffusion imaging […]